Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MNK-1411
- Development stage
- Phase 2
- Lead developer
- Mallinckrodt
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
MNK-1411 is an investigational drug developed by Mallinckrodt for the treatment of Duchenne Muscular Dystrophy (DMD). It is a depot formulation of cosyntropin acetate, also known as tetracosactide, a synthetic 24 amino acid melanocortin receptor agonist. The drug is designed for prolonged release and is believed to reduce inflammation and muscle damage by stimulating melanocortin receptors, potentially delaying DMD progression and improving motor function. MNK-1411 is also approved and marketed outside the U.S. for certain autoimmune and inflammatory conditions.
- Brand names
- Cortrophin SCortrosintaCortrosynSynacthenSynacthen DepotSynacthene
- Other names
- Cosyntropin acetateTetracosactide Hexaacetate
02
Targets
MCR (Melanocortin receptor family)
Beyond the preview
Go deeper on MNK-1411.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MNK-1411.